A Phase 3 interventional study of Ublituximab and Ublituximab in Relapsing Multiple Sclerosis, sponsored by TG Therapeutics, Inc.. Active, not recruiting at 48 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by TG Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ublituximab in Multiple Sclerosis — 5 open to participants now, 7 under way, 4 of them phase 3. ublituximab · Multiple Sclerosis.
Among the 10 studies testing ublituximab in Multiple Sclerosis, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 6th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →5 of the 10 studies testing ublituximab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
TG Therapeutics, Inc. · Sites in Bosnia and Herzegovina, Georgia, North Macedonia and 3 more countries
Ages 18–65
Johns Hopkins University · Sites in United States
Ages 18–65
Northwestern University · Sites in United States
Ages 18–70
TG Therapeutics, Inc. · Sites in United States, Poland
Ages 18–65
By country, each count listing its studies:
ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 6 · Phase 4 2
First in 2016; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 355 across the 10 interventional studies. Of the 3 that completed or were terminated, 3 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 3 most frequent:
TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
12 studies in Multiple Sclerosis by TG Therapeutics, Inc.: 6 open now, 9 under way, 4 of them phase 3. Of 3 finished, 3 (100%) have results posted.
Among the 12 studies in Multiple Sclerosis by TG Therapeutics, Inc., this one is one of 2 that started in 2025, is one of 5 in phase 3, and was the 10th registered.
TG Therapeutics, Inc.’s Multiple Sclerosis studies by the year they started, since 2016.
2 of the studies testing ublituximab in Multiple Sclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT07503873TG Therapeutics, Inc.A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing ublituximab in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among TG Therapeutics, Inc.’s 12 in Multiple Sclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.
This is a Phase 3, open label, parallel-group, multicenter study in participants with RMS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approved dosage.
Biological: Ublituximab
New regimen.
Biological: Ublituximab
New regimen.
Biological: Ublituximab
Administered as an IV infusion.
Also known as: TG-1101
Administered as an SC injection.
Also known as: TG-1101
Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab
Time frame: Up to Week 24
Minimum Plasma Concentration (Cmin) of Ublituximab
Time frame: Up to Week 24
Average Concentration at Steady State (Cavg,ss) of Ublituximab
Time frame: Up to Week 120
Maximum Plasma Concentration (Cmax) of Ublituximab
Time frame: Up to Week 120
Time to Maximum Plasma Concentration (Tmax) of Ublituximab
Time frame: Up to Week 120
Last Observed Concentration (Clast) of Ublituximab
Time frame: Up to Week 120
Area Under the Curve From Week 0 to Week 120 (AUC0-120) of Ublituximab
Time frame: Up to Week 120
Concentration From Time 0 to Time of Last Concentration (AUClast) of Ublituximab
Time frame: Up to Week 120
Time of Last Concentration (Tlast) of Ublituximab
Time frame: Up to Week 120
Participants B Cell Counts
Time frame: Up to Week 120
Incidence of Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to Week 120
Total Number of Gadolinium (Gd) enhancing T1 Lesions Per Magnetic Resonance Imaging (MRI) Scan
Time frame: Up to Week 96
Total Number of New or Enlarging T2 lesions Per MRI Scan
Time frame: Up to Week 96
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Oct 2026, 15 months after the start.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 15 months is below that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ublituximab